IQVIA Logo
Contact Us
Olink-machine

Olink — Scalable, multiplexed biomarkers

IQVIA Laboratories Protein Biomarkers performs Olink testing to support efficiency and precision in your clinical trials.

Request a Quote
Home / Protein Biomarkers / Olink - Scalable, multiplexed biomarkers

IQVIA Laboratories Protein Biomarkers — formerly know as Rules-Based Medicine —  a leader in testing soluble proteins for 25 years — performs Olink testing to support efficiency and precision in your clinical trials. 

 

Olink’s proximity extension assay (PEA®) technology delivers the throughput you need without compromising specificity or scalability.

 

Whether you need a small panel of focused biomarkers or a comprehensive exploratory assessment, we have an Olink option to meet your needs.  See our Target 48 and Target 96 panels below and click here for Explore HT.

 
Olink-certified service provider for Explore HT, Target, Flex and Focus.
5400+ biomarkers using Explore HT.
From broad biomarker discovery with Explore HT to focused therapeutic panels using Target 48, Target 96, Flex and Focus.
IQVIA Laboratories Protein Biomarkers —formerly Rules-Based Medicine— brings >25 years of experience in multiplexed biomarker development.

Proximity extension assay (PEA®) technology

RBM_OlinkBrochure_Final_Digital (3)-23

 

diagram1The Olink PEA technology employs a dual-recognition approach using antibody pairs labeled with complementary DNA oligonucleotides. 

RBM_OlinkBrochure_Final_Digital (3)-2

 

diagram2

When the antibody pair binds to the target protein, the oligonucleotides are brought into proximity and hybridize, creating a unique DNA barcode for each protein.

RBM_OlinkBrochure_Final_Digital (3)-4

 

Iconography_Finals_Color_BarcodeThis DNA barcode is then extended and amplified by polymerase chain reaction (PCR) and measured by quantitative PCR (qPCR) or next-generation sequencing (NGS).

Olink is well suited to:
RBM_OlinkBrochure_Final_Digital (3)-2Evaluate therapeutic effects

Accurately measure at baseline and after treatment to understand the dynamic changes associated with a therapeutic candidate.
RBM_OlinkBrochure_Final_Digital (3)-2Understand disease onset and mechanism of action

Certain biomarkers are present years before diagnosis. Olink can help identify the relevant proteomic changes.
RBM_OlinkBrochure_Final_Digital (3)-2Develop biomarker signatures

Explore HT measures thousands of proteins at once. Longitudinal studies can help you understand proteomic profiles for different diseases.
RBM_OlinkBrochure_Final_Digital (3)-2Identify drug targets

Disease-specific proteomic signatures can help identify potential drug targets.
Exceptional sensitivity and specificity

Detect proteins at femtograms per mililiter
Low sample volume

Numerous assays performed from a single sample
Built-in quality controls

Internal and external controls in all biomarker panels
Scalability

Take your findings from discovery toward clinical translation
Disease-specific panels

Measure the markers relevant to your therapeutic area

Available Olink products
Explore HT
Target 48
Target 98

5400+ proteins from a single sample

  • High-throughput, scalable biomarker discovery and analysis
  • Integrates with other omics data for a comprehensive picture
  • Useful for identifying disease targets, pharmacokinetics, longitudinal and population-based studies

Carefully selected biomarkers for a comprehensive view:

Biomarkers targeting specific therapeutic areas:

Target 48 Cytokine

Target 48 Immune Surveillance

Target 96 Immuno-Oncology

Target 96 Oncology II

Target 96 Cardiovascular II

Target 96 Cardiovascular III

Target 96 Immune Response

Target 96 Inflammation

Target 96 Metabolism

Target 96 Neuro Exploratory